Immunological response against SARS-CoV-2 following full-dose administration of Comirnaty® COVID-19 vaccine in nursing home residents
Objectives: The current study was aimed at examining SARS-CoV-2 immune responses following two doses of Comirnaty® COVID-19 vaccine among elderly people in nursing homes. Methods: A prospective cohort study in a representative sample from nursing homes in Valencia (n ¼ 881; males: 271, females 610;...
| Authors: | , , , , , , , , , , |
|---|---|
| Format: | article |
| Publication Date: | 2021 |
| Country: | España |
| Institution: | Universidad Católica de Valencia San Vicente Mártir |
| Repository: | RIUCV. Repositorio de la Universidad Católica de Valencia San Vicente Mártir |
| Language: | English |
| OAI Identifier: | oai:riucv.ucv.es:20.500.12466/3268 |
| Online Access: | http://hdl.handle.net/20.500.12466/3268 |
| Access Level: | Open access |
| Keyword: | Comirnaty® COVID-19 vaccine Nursing home residents SARS-CoV-2 SARS-CoV-2-S antibodies 3202 Epidemiología 3205.05 Enfermedades Infecciosas |
| Summary: | Objectives: The current study was aimed at examining SARS-CoV-2 immune responses following two doses of Comirnaty® COVID-19 vaccine among elderly people in nursing homes. Methods: A prospective cohort study in a representative sample from nursing homes in Valencia (n ¼ 881; males: 271, females 610; median age, 86 years) recruited residents using a random one-stage cluster sampling approach. A lateral flow immunochromatography device (LFIC) (OnSite COVID-19 IgG/ IgM Rapid Test; CTK BIOTECH, Poway, CA, USA) was used as the front-line test for detecting SARS-CoV-2- Spike (S)-specific antibodies in whole blood obtained using a fingerstick. Residents returning negative LFIC results underwent venipuncture and testing for presence of SARS-CoV-2-S-reactive antibodies and T cells using the Roche Elecsys® Anti-SARS-CoV-2 S (Roche Diagnostics, Pleasanton, CA, USA), the LIAISON® SARS-CoV-2 TrimericS IgG assay (Diasorin S.p.A, Saluggia, Italy) and by flow cytometry, respectively. Results: The SARS-CoV-2-S antibody detection rate in nursing home residents was 99.6% (283/284) and 98.3% (587/597) for SARS-CoV-2 recovered and naïve residents, respectively, within a median of 99 days (range 17e125 days) after full vaccination. Three out of five residents lacking SARS-CoV-2-S antibodies had detectable S-reactive CD8þ and/or CD4þ T cells. In addition, 50/50 and 40/50 participants with detectable SARS-CoV-2 antibodies also had SARS-CoV-2-S-reactive interferon-g-producing CD4þ and CD8þ T cells, respectively |
|---|